Printer Friendly

SMITHKLINE BEECHAM GIVES $1 MILLION TO ARTHRITIS FOUNDATION FOR MODEL PROJECT

 SMITHKLINE BEECHAM GIVES $1 MILLION
 TO ARTHRITIS FOUNDATION FOR MODEL PROJECT
 LAS VEGAS, Nev., April 12 /PRNewswire/ -- SmithKline Beecham (ADS - NYSE: SBH) today presented the Arthritis Foundation with $1 million to fund a novel project to improve the quality of life and lessen the disability of Americans with arthritis.
 Presented here at the Arthritis Foundation telethon, the grant will fund the San Mateo Arthritis Project, which will make arthritis resources more accessible in San Mateo, Calif., and extend the lessons learned there to communities across the country. The Arthritis Foundation intends to make San Mateo a national model that every community can follow to help its citizens with arthritis enjoy a better quality of life.
 "This generous grant from SmithKline Beecham will allow us to implement a highly innovative project that will increase our outreach to the 37 million Americans with arthritis," said Don L. Riggin, president and chief executive officer of the Arthritis Foundation.
 SmithKline Beecham is making the donation in conjunction with the introduction of Relafen(R) (nabumetone), their new medicine. "We recognize that medication is not the only important element in arthritis care," said J.P. Garnier, president of SmithKline Beecham's pharmaceutical business in North America. "We are proud to support a program that will improve the quality of life of Americans with arthritis."
 The Arthritis Foundation, headquartered in Atlanta, has 71 chapters nationwide. Its mission is to support research to find ways to cure and prevent arthritis and to improve the quality of life for those affected by arthritis. The Arthritis Foundation will oversee the San Mateo Arthritis Project along with a community board of directors and a national board of advisers.
 SmithKline Beecham is a worldwide research-intensive health-care company with 1991 sales of $8.7 billion and an annual research budget of more than $800 million. In addition to arthritis, SB scientists focus on the discovery of drugs to treat infection, cardiovascular disease, central nervous system disorders, and gastrointestinal disease.
 -0- 4/12/92
 /CONTACT: Jeremy Heymsfeld of SmithKline Beecham, 215-751-5166, or Kathy Varjavandi of Edelman, 212-704-8217, for SmithKline Beecham/
 (SBH) CO: SmithKline Beecham; Arthritis Foundation ST: Pennsylvania IN: MTC SU:


CK-OS -- NYSU001 -- 7499 04/12/92 12:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1992
Words:365
Previous Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR APRIL 12, 1992
Next Article:SNO COUNTRY REPORTS OFFICIAL SKI REPORT FOR APRIL 12, 1992


Related Articles
RELAFEN APPROVED FOR U.S. MARKETING: NEW CLASS OF NSAID WITH LOW ULCER RISK
THE CREATION OF A LIVING LABORATORY FOR OPTIMAL ARTHRITIS CARE: SAN MATEO ARTHRITIS PROJECT ANNOUNCED
SAN MATEO, CALIF., NAMED NATIONAL SITE FOR MODEL ARTHRITIS CARE PROJECT
RELAFEN AVAILABLE IN THE UNITED STATES: NEW CLASS OF NSAID WITH LOW ULCER INCIDENCE
TEMPLE UNIVERSITY HOSPITAL TO HOLD SMITHKLINE BEECHAM DEPARTMENT OF DIAGNOSTIC IMAGING DEDICATION CEREMONY 2 P.M. TOMORROW
BRITISH BIO-TECHNOLOGY AND SMITHKLINE BEECHAM SIGN AGREEMENT FOR RESEARCH COLLABORATION
FREE ARTHRITIS FOUNDATION MEMBERSHIPS ARE OFFERED, COMPLIMENTS OF SMITHKLINE BEECHAM
IDEC PHARMACEUTICALS AND SMITHKLINE BEECHAM EXPAND 'PRIMATIZED' ANTIBODY COLLABORATION TO INCLUDE ASIA
SMITHKLINE BEECHAM LAUNCHES DIRECT-TO-PATIENT AWARENESS CAMPAIGN FOR PRESCRIPTION ARTHRITIS DRUG
POSITIVE STEPS(TM) LAUNCHED BY SMITHKLINE BEECHAM TO HELP ARTHRITIS PATIENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters